Chimerix, Inc. (CMRX) Stock Analysis
DELISTED 2025
What happened to Chimerix, Inc. (CMRX) stock?
Chimerix, Inc. (CMRX) no longer trades on public markets. It was delisted in April 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chimerix, Inc. (CMRX) trades at $8.54. Chimerix, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Market cap: $801M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for CMRX: CMRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CMRX against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
CMRX: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Chimerix, Inc. (CMRX) Healthcare & Pipeline Overview
Chimerix, Inc. is a biopharmaceutical company specializing in the development of treatments for serious diseases, including TEMBEXA for smallpox. With a focus on oncology, Chimerix is advancing clinical-stage programs targeting tumors and hematological malignancies, positioning itself within the competitive biotechnology landscape.
What Is the Investment Thesis for CMRX?
Chimerix presents a compelling investment thesis centered on its approved product, TEMBEXA, and its pipeline of oncology-focused clinical programs. Key value drivers include the continued revenue generation from TEMBEXA as a smallpox countermeasure and the potential clinical success of ONC201, ONC206, ONC212, and DSTAT. Upcoming catalysts include the progression of ONC206 into further clinical trial phases and potential partnership agreements for its oncology assets. The company's negative profit margin of -41692.0% highlights the need for successful commercialization of its pipeline assets. With a market cap of $801M and a beta of -0.18, Chimerix offers a unique risk-reward profile within the biotechnology sector.
Based on FMP financials and quantitative analysis
CMRX Key Highlights
TEMBEXA is an approved medical countermeasure for smallpox, providing a consistent revenue stream.
- Clinical-stage programs ONC201, ONC206, ONC212, and DSTAT target significant unmet needs in oncology.
- Gross margin of 100.0% indicates strong profitability on product sales, primarily TEMBEXA.
- Market capitalization of $801M reflects investor valuation of current assets and pipeline potential.
- Beta of -0.18 suggests low correlation with overall market movements, potentially offering portfolio diversification.
Who Are CMRX's Competitors?
CMRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GNFTF Genfit S.A. | $16.28 | +0.00% | $816M | 73 |
| RIGL Rigel Pharmaceuticals, Inc. | $45.77 | +1.15% | $847M | 92 |
| TBPH Theravance Biopharma, Inc. | $17.01 | +0.35% | $882M | 95 |
| ZVRA Zevra Therapeutics, Inc. | $11.87 | -0.17% | $702M | 93 |
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
| CLYM Climb Bio, Inc. | $17.28 | +1.53% | $990M | 76 |
| VERV Verve Therapeutics, Inc. | $11.13 | +0.27% | $994M | 71 |
| CRMD CorMedix Inc. | $8.18 | -0.58% | $642M | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CMRX's Key Strengths?
Approved product (TEMBEXA) provides a revenue stream.
- Pipeline of clinical-stage oncology programs.
- Strategic partnerships with BARDA, Cantex Pharmaceuticals, and SymBio Pharmaceuticals.
- Experienced management team.
What Are CMRX's Weaknesses?
High operating expenses due to research and development activities.
- Dependence on TEMBEXA for revenue.
- Negative profit margin.
- Clinical trial risks associated with pipeline programs.
What Could Drive CMRX Stock Higher?
Clinical trial results for ONC206 in solid tumors.
- Potential partnership agreements for oncology assets.
- Continued revenue generation from TEMBEXA sales.
- Advancement of ONC212 and DSTAT programs.
What Are the Key Risks for CMRX?
Negative return on equity (-56.2%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures for pipeline programs.
- Regulatory delays or rejections.
- Competition from other pharmaceutical companies.
- Dependence on TEMBEXA for revenue.
- High operating expenses.
What Are the Growth Opportunities for CMRX?
- Expansion of TEMBEXA's Market: Chimerix can explore opportunities to expand the market for TEMBEXA beyond its current indication as a smallpox countermeasure. This could involve seeking approvals for additional indications or expanding government stockpiling contracts. The global market for antiviral drugs is projected to reach $55 billion by 2030, providing a significant opportunity for TEMBEXA to capture a larger share. Success in this area would provide a stable revenue stream to fund further pipeline development.
- Advancement of ONC201 Program: ONC201 targets tumors with the H3 K27M mutation, a significant unmet need in recurrent diffuse midline glioma patients. Positive clinical trial results and subsequent regulatory approval could lead to substantial revenue generation. The market for glioma treatments is expected to reach $2.5 billion by 2028. Chimerix's focus on this specific mutation provides a targeted approach with potential for high efficacy.
- Development of ONC206 and ONC212: ONC206 and ONC212 represent novel approaches to treating solid tumors and hematological malignancies. Successful completion of Phase I clinical trials and progression into later-stage development could attract significant investor interest and partnership opportunities. The broader oncology market is estimated at over $200 billion annually, offering substantial potential for these programs.
- Strategic Partnerships and Licensing Agreements: Chimerix can pursue additional strategic partnerships and licensing agreements to expand the reach of its products and pipeline. Collaborations with larger pharmaceutical companies could provide access to resources and expertise, accelerating development and commercialization efforts. The company's existing agreements with BARDA, Cantex Pharmaceuticals, and SymBio Pharmaceuticals demonstrate its ability to forge successful partnerships.
- Expansion into New Therapeutic Areas: While currently focused on oncology and infectious diseases, Chimerix could explore opportunities to expand into new therapeutic areas with unmet medical needs. This could involve leveraging its expertise in drug development and its existing infrastructure to target other diseases with significant market potential. The company's scientific expertise could be applied to develop novel therapies for autoimmune disorders or neurological conditions.
What Are CMRX's Competitive Advantages?
- Patent protection for TEMBEXA and other pipeline products.
- Regulatory exclusivity for TEMBEXA as a smallpox countermeasure.
- Specialized expertise in developing antiviral and oncology therapies.
- Established relationships with government agencies and pharmaceutical companies.
What Does CMRX Do?
Chimerix, Inc., founded in 2000 and headquartered in Durham, North Carolina, is a biopharmaceutical company dedicated to enhancing the lives of patients with serious diseases. The company's approved product, TEMBEXA (brincidofovir), is a lipid conjugate antiviral developed as a medical countermeasure for smallpox, functioning through the inhibition of viral DNA synthesis. Beyond TEMBEXA, Chimerix is actively engaged in clinical-stage development programs focused on oncology. These include ONC201, targeting tumors with the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone with enhanced DRD2 antagonism, currently in Phase I clinical trials for solid tumors; ONC212, an imipridone agonist targeting GPR132 and ClpP for solid tumors and hematological malignancies; and dociparstat sodium (DSTAT), designed to inhibit key proteins implicated in resistance to chemotherapy in acute myeloid leukemia. Chimerix has established strategic license agreements with Biomedical Advanced Research and Development Authority (BARDA) for the development of brincidofovir, Cantex Pharmaceuticals, Inc. for a glycosaminoglycan compound, and SymBio Pharmaceuticals for BCV across various human indications. The company's focus on innovative therapies and strategic partnerships underscores its commitment to addressing unmet medical needs.
What Products and Services Does CMRX Offer?
- Develops and commercializes medicines for serious diseases.
- Offers TEMBEXA (brincidofovir) as a medical countermeasure for smallpox.
- Advances clinical-stage programs targeting tumors with the H3 K27M mutation.
- Develops ONC206, an imipridone for treating solid tumors.
- Develops ONC212, an imipridone agonist for solid tumors and hematological malignancies.
- Develops dociparstat sodium (DSTAT) for acute myeloid leukemia.
How Does CMRX Make Money?
- Develops and commercializes pharmaceutical products.
- Generates revenue through sales of TEMBEXA to government agencies and other entities.
- Out-licenses certain technologies and products to other pharmaceutical companies.
- Advances clinical-stage programs through research and development activities.
What Industry Does CMRX Operate In?
Chimerix operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory hurdles, and substantial investment in research and development. The market for oncology therapeutics is particularly competitive, with numerous companies vying to develop novel treatments for various cancers. Chimerix's focus on specific tumor mutations and resistance mechanisms positions it within a niche segment of the oncology market. The company's approved smallpox countermeasure, TEMBEXA, provides a stable revenue base, differentiating it from many other biotechnology companies that rely solely on pipeline development.
Who Are CMRX's Key Customers?
- Government agencies responsible for biodefense and public health.
- Hospitals and healthcare providers.
- Patients with smallpox and other serious diseases.
- Pharmaceutical companies through licensing agreements.
Company Profile
Chimerix, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Durham, US. The company is led by CEO Michael T. Andriole. CMRX has traded publicly since 2013.
Financial Health
Chimerix, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 10.02 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Chimerix, Inc. stands at -56.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -60.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.70 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.5%, the inverse of the P/E and a quick read on earnings relative to price.
CMRX Valuation & Market Position
With a $801M market cap, Chimerix, Inc. sits in the small-cap segment of the market.
Forward Outlook
Wall Street analysts project Chimerix, Inc. revenue of about $65.3M for fiscal 2026, with EPS near $-0.69.
CMRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's pipeline and strategic direction.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in antiviral treatments.
- Analyst commentary points to improving relationships with key partners, enhancing market positioning.
- Recent press releases indicate progress in clinical trials, generating optimism among investors and stakeholders.
Bear Case
- Concerns over the competitive landscape have surfaced, with emerging therapies posing risks to Chimerix's market share.
- Some community members express skepticism about the timeline for product approvals, fearing delays could hinder growth.
- Recent financial reports indicate ongoing challenges in revenue generation, raising questions about sustainability.
- Market perception remains cautious, as investors weigh the potential of the pipeline against the backdrop of broader industry uncertainties.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CMRX Latest News
No recent news available for CMRX.
Leadership: Michael T. Andriole
CEO
Michael T. Andriole serves as the CEO of Chimerix, Inc., leading a team of 79 employees. His career spans various leadership roles within the pharmaceutical and biotechnology industries. He brings extensive experience in strategic planning, business development, and commercialization of pharmaceutical products. His educational background includes advanced degrees in relevant scientific fields, providing a strong foundation for his leadership in the biopharmaceutical sector.
Track Record: Under Michael T. Andriole's leadership, Chimerix has focused on advancing its pipeline of oncology-focused clinical programs and maximizing the value of TEMBEXA. Key achievements include the progression of ONC206 into Phase I clinical trials and the maintenance of strategic partnerships. His strategic decisions have aimed to position Chimerix for long-term growth and success in the competitive biotechnology landscape.
CMRX Healthcare Stock FAQ
What happened to Chimerix, Inc. (CMRX) stock?
Chimerix, Inc. (CMRX) no longer trades on public markets. It was delisted in April 2025. The figures below are historical and are not a current quote.
Can I still buy CMRX shares?
No. CMRX stopped trading on public markets in April 2025, so the shares are not available through a broker. Anything you see quoted for CMRX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before CMRX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Chimerix, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Chimerix, Inc. do?
Chimerix, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for serious diseases. The company's approved product, TEMBEXA (brincidofovir), serves as a medical countermeasure for smallpox. Additionally, Chimerix is actively engaged in advancing a pipeline of clinical-stage oncology programs, targeting tumors and hematological malignancies.
What do analysts say about CMRX stock?
Analyst coverage of Chimerix reflects a focus on the company's pipeline potential and the revenue generated by TEMBEXA. Key valuation metrics include market capitalization and potential revenue from future product sales. Growth considerations center on the successful completion of clinical trials and regulatory approvals for the company's oncology programs.
What are the main risks for CMRX?
Chimerix faces several key risks, including the potential for clinical trial failures, regulatory delays, and competition from other pharmaceutical companies. The company's dependence on TEMBEXA for revenue also poses a risk, as changes in government funding or the emergence of alternative treatments could impact sales.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be subject to change.
- Clinical trial outcomes are inherently uncertain.